In skeletal muscle, Mitsugumin 53 (MG53), also known as muscle-specific tripartite motif 72, reportedly interacts with dysferlin to regulate membrane repair. To better understand the interactions between dysferlin and MG53, we conducted immunoprecipitation (IP) and pull-down assays. Based on IP assays, the C2A domain in dysferlin associated with MG53. MG53 reportedly exists as a monomer, a homodimer, or an oligomer, depending on the redox state. Based on pull-down assays, wild-type dysferlin associated with MG53 dimers in a Ca2+-dependent manner, but MG53 oligomers associated with both wild-type and C2A-mutant dysferlin in a Ca2+-independent manner. In pull-down assays, a pathogenic missense mutation in the C2A domain (W52R-C2A) inhibited the association between dysferlin and MG53 dimers, but another missense mutation (V67D-C2A) altered the calcium sensitivity of the association between the C2A domain and MG53 dimers. In contrast to the multimers, the MG53 monomers did not interact with wild-type or C2A mutant dysferlin in pull-down assays. These results indicated that the C2A domain in dysferlin is important for the Ca2+-dependent association with MG53 dimers and that dysferlin may associate with MG53 dimers in response to the influx of Ca2+ that occurs during membrane injury.
To examine the biological role of the association between dysferlin and MG53, we co-expressed EGFP-dysferlin with RFP-tagged wild-type MG53 or RFP-tagged mutant MG53 (RFP-C242A-MG53) in mouse skeletal muscle, and observed molecular behavior during sarcolemmal repair; it has been reported that the C242A-MG53 mutant forms dimers, but not oligomers. In response to membrane wounding, dysferlin accumulated at the injury site within 1 second; this dysferlin accumulation was followed by the accumulation of wild-type MG53. However, accumulation of RFP-C242A MG53 at the wounded site was impaired relative to that of RFP-wild-type MG53. Co-transfection of RFP-C242A MG53 inhibited the recruitment of dysferlin to the sarcolemmal injury site. We also examined the molecular behavior of GFP-wild-type MG53 during sarcolemmal repair in dysferlin-deficient mice which show progressive muscular dystrophy, and found that GFP-MG53 accumulated at the wound similar to wild-type mice. Our data indicate that the coordination between dysferlin and MG53 plays an important role in efficient sarcolemmal repair.
Funding StatementThis study was partly supported by intramural Research Grant 23-4 (YKH) and 23-5 (CM, IN) for Neurological and Psychiatric Disorders of NCNP; partly by Research on Intractable Diseases, Comprehensive Research on Disability Health and Welfare (YKH, IN), and Applying Health Technology from the Ministry of Health Labour and Welfare (IN); and partly by JSPS KAKENHI Grant Numbers of 18590966 (CM), 24390227 (YKH), and 24659437 (YKH).
Dysferlin is a sarcolemmal protein, and dysferlin deficiency causes Miyoshi myopathy (MM) and limb girdle muscular dystrophy type 2B (LGMD2B) [1,2]. Based on the observation that dysferlin accumulates at wound sites in myofibers in a Ca2+-dependent manner, dysferlin is thought to mediate Ca2+-dependent sarcolemmal repair .
Mitsugumin 53 (MG53), also known as muscle-specific tripartite motif 72, is a recently identified protein involved in membrane repair in skeletal muscle . Mice lacking MG53 suffer progressive myopathy , similar to dysferlin-null mice . MG53 is localized in intracellular vesicles and plasma membranes in skeletal muscle, and it accumulates at injury sites in an oxidation-dependent, but not Ca2+-dependent, manner .
MG53 interacts with dysferlin and caveolin-3 to regulate sarcolemmal repair . When expressed in C2C12 myoblasts that lack endogenous MG53, damaged membrane sites cannot be repaired in the presence of GFP-dysferlin, however, co-transfection of MG53 and GFP-dysferlin in these myoblasts results in GFP-dysferlin accumulation at injury sites . These findings indicated that recruitment of dysferlin to the injury site of the membrane depends on MG53. However, it remains unclear whether the absence of dysferlin perturbs recruitment of MG53 to the injury site for membrane repair. A previous report has demonstrated the association of dysferlin with MG53 with co-immunoprecipitation (IP) assays using mouse skeletal muscle and C2C12 myoblasts transfected with dysferlin and MG53 . However, which protein domains participate in this interaction between dysferlin and MG53 and whether this interaction is dependent on Ca2+ remain unclear. MG53 oligomerizes via disulfide bonds  and forms homodimers via a leucine-zipper motif in the coiled-coil domain . The interaction between dysferlin proteins and MG53 monomers or oligomers has not been characterized in detail. To understand the precise role of dysferlin and MG53 in sarcolemmal repair, it would be helpful to determine whether dysferlin associates with MG53 monomers, oligomers, or both in a Ca2+-dependent manner.
Thus, to examine the biological role of the association between dysferlin and MG53, we used the following strategy to examine the effect of the absence of MG53 oligomers on dysferlin. We co-transfected mouse skeletal muscle with wild-type dysferlin-EGFP and RFP-tagged wild-type MG53 or a RFP-tagged MG53 mutant (RFP-C242A –MG53), and conducted a membrane-repair assay using a two-photon laser microscope. The C242A–MG53 mutant has been reported to form dimers, but not oligomers . There is no report of simultaneous observation of dysferlin and MG53 during sarcolemmal repair; however, we have successfully performed real-time imaging of dysferlin-GFP and MG53-RFP after membrane injury in mouse skeletal muscle.
Dysferlin protein is absent or severely reduced in the skeletal muscle of patients with dysferlinopathy  and of SJL and A/J mice with mutations in the dysferlin genes . To examine whether the absence of dysferlin affects the recruitment of MG53 to injury sites, we transfected skeletal muscle from dysferlin-deficient SJL and A/J mice with EGFP-MG53 and conducted membrane repair assays. These experiments are helpful in elucidating the molecular pathology of dysferlinopathy and revealed that MG53 accumulated in the skeletal muscles of dysferlin-deficient mice, which develop progressive muscular dystrophy.
We present evidence indicating that efficient sarcolemmal repair requires both dysferlin and MG53.
Immunoprecipitation. To examine the interaction between MG53 and dysferlin, mouse gastrocnemius muscles were lysed in lysis buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, and Complete mini EDTA-free protease inhibitor cocktail (Roche)  supplemented with 1 mM CaCl2 or 2 mM EGTA. Lysates pre-cleared with Protein A/G agarose (Pierce) were incubated with polyclonal antibodies against mouse MG53  or mouse dysferlin; the anti-dysferlin antibody was made in rabbit by injecting bacterial recombinant protein containing residues 1669 to 1790. The immunoprecipitated proteins were separated by SDS-PAGE and detected on immunoblots using the same antibodies used for IP or the anti-human dysferlin monoclonal antibody, NCL-Hamlet (Novocastra Laboratories).
A human MG53 cDNA was amplified by PCR and subcloned into pFLAG-CMV-4 (Sigma). Wild-type and truncated human dysferlin that were each tagged with c-myc were generated previously . We also created five truncated human dysferlin constructs with the C2A domain (aa 1-149, 1-349, and 1-1080) and without the C2A domain (aa 130-2080 and 1081-2080). The sequence of each construct was verified by DNA sequencing. FuGENE 6 or E-xtremeGENE 9 (Roche) was used to transiently transfect COS-7 cells with MG53 and wild-type or mutant dysferlin constructs. Transfectants were cultured for 48 h and subsequently lysed in the same lysis buffer used to lyse mouse muscle, except that this buffer lacked CaCl2 and EGTA. Lysates pre-cleared with Protein G-Sepharose (GE Healthcare) were incubated with anti-FLAG (M2, Sigma) or anti-c-myc (9E10, Santa Cruz Biotechnology) monoclonal antibodies; Protein G-Sepharose was then added. Immunoprecipitated proteins were analyzed by immunoblotting using M2 and anti-c-myc polyclonal (A14, Santa Cruz Biotechnology) antibodies.
Pull-down assay. Fragments of the dysferlin C2A domain (corresponding to aa 1-129 of human dysferlin) were amplified as cDNA by PCR and subcloned into pGEX-5X-3 (GE Healthcare). Dysferlin p.W52R (TGG to CGG at c.527-529) and p.V67D (GTG to GAT at c.572-574) mutations were introduced by PCR using appropriate primers. GST fusion proteins expressed in BL21 E. coli were purified using sarkosyl  and bound to glutathione Sepharose 4B (GE Healthcare). COS-7 cells overexpressing FLAG-tagged human MG53 were lysed in lysis buffer containing 10 mM Na2HPO4, 1.8 mM KH2HPO4, 1% NP-40 (pH 7.4), 2 mM EGTA, various concentration of CaCl2, and Complete mini EDTA-free protease inhibitor cocktail. EGTA was used to chelate the free Ca2+ in solution and CaCl2 at various concentrations. The free calcium concentration was calculated using the free software CALCON3.6. Lysates were centrifuged to remove cellular debris, supplemented with 5 mM N-methylmaleimide (NEM) or 5 mM dithiothreitol (DTT), and finally subjected to protein cross-linking by treating with 2 mM glutaraldehyde (GA) for 5 min at room temperature, which was quenched with 100 mM Tris-HCl (pH 7.5) . The cross-linked lysates were diluted with 75 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 2 mM EGTA, various concentrations of CaCl2, and Complete mini EDTA-free protease inhibitor cocktail. Lysates pre-cleared with GST bound to glutathione Sepharose 4B were divided into aliquots and incubated with wild-type, p.W52R, and p.V67D dysferlin C2A-GST fusion protein bound to beads for 2 hr at 4°C. After three washes in lysis buffer containing 75 mM Tris-HCl (pH 7.5), 2× sample buffer (125 mM Tris-HCl (pH 6.8), 4% SDS, 20% (v/v) glycerol, and 0.004% bromophenol blue) was added to the beads, and the mixtures were incubated for 10 min at 85°C. Bound proteins were separated by SDS-PAGE and subjected to immunoblotting with the anti-FLAG antibody M2.
In vivo transfection and membrane repair assay. Twenty micrograms of N-terminal RFP-tagged human MG53 cDNA/pcDNA3.1 and/or C-terminal GFP-tagged human dysferlin cDNA/pcDNA3.1 plasmid DNA were injected into the flexor digitorum brevis of anesthetized, 4-week-old male C57BL6J and dysferlin-deficient SJL and A/J mice. Electroporation of plasmid DNA was performed using an electric pulse generator (CUY21SC, NEPAGENE) as described previously . Seven days after electroporation, skeletal muscle myocytes (for whole-mount viewing) or individual myofibers were isolated and subjected to plasma membrane injury created by a two-photon laser microscope, LSM 710NLO with GaAsp Detectors (Zeiss) and Chameleon Vision II System (Coherent). Myofiber wounding using the 820-nm infrared laser and resealing analysis based on the kinetics and extent of FM1-43 or 4-46 dye (Molecular Probes) entry through open disruptions was carried out as previously described [3,13,14].
Ethics Statement. All experiments involving animals were performed according to the Procedure for Handling Experiments involving Animals of AIST (National Institute of Advanced Industrial Science and Technology) and approved by the Institutional Animal Care and Use Committee of AIST.
Association of MG53 and dysferlin in mouse skeletal muscle
We used an IP assay with protein from mouse muscle to confirm that endogenous MG53 associates with dysferlin in vivo. MG53 and dysferlin associated only in the absence of EGTA and CaCl2 (Fig. 1). The same result was obtained using C2C12 myotubes (data not shown). MG53 was specifically co-immunoprecipitated by the anti-dysferlin antibody, and conversely dysferlin was specifically co-immunoprecipitated by the anti-MG53 antibody. Thus, we confirmed that endogenous MG53 and endogenous dysferlin form a protein complex in mouse skeletal muscle without EGTA or CaCl2 supplementation.
Identification of the MG53-associating domain of dysferlin
Next, we used IP to define the region of dysferlin that associates with MG53. Specifically, we used transient co-transfection to introduce a construct encoding full-length human MG53 tagged with FLAG and a construct encoding human dysferlin tagged with c-myc into COS-7 cells; for each co-transfection, full-length dysferlin or one of five deletion mutant forms of tagged dysferlin was used (Fig. 2). For deletion mutants that lacked the C-terminal domain of dysferlin, the transmembrane domain of dysferlin was retained to increase protein stability . Transfectants were lysed in the same buffer that was used for IP assays of mouse skeletal muscle extract, except that this buffer lacked EGTA and CaCl2. Full-length dysferlin and deletion mutants that retained the N-terminal C2 (C2A) domain of dysferlin were co-immunoprecipitated by anti-MG53 antibody. In contrast, dysferlin mutants that lacked this N-terminal domain, Δ2-1080 and Δ2-129, failed to interact with MG53. These results indicated that the C2A domain of dysferlin was necessary for association with MG53.
Characterization of the association of dysferlin C2A domain with MG53 monomers and MG53 oligomer
C2 domains are known to bind to phospholipids and/or proteins in a Ca2+-dependent or Ca2+-independent manner . Therefore, we used a pull-down assay to examine whether the Ca2+ concentration affected the association between MG53 and the dysferlin C2A domain. We used lysis buffer containing 75 mM Tris to reduce the change in pH that can result from the addition of CaCl2, to examine the calcium-dependency of the association between dysferlin and MG53. Reportedly, MG53 can exist as a monomer or an oligomer, depending on the redox state . We used DTT for monomerization of MG53 by reducing sulfhydryl groups. Addition of 5 mM DTT resulted in complete dissociation of all MG53 oligomers (Fig. 3). To conduct a pull-down assay for MG53 oligomers, we treated cell lysates with an alkylating reagent, NEM, which reacts with sulfhydryl groups to form stable thioether bonds . Multimers of MG53 were stabilized by chemical cross-linking with GA. Addition of 5 mM NEM to cell lysates resulted in oligomerization of MG53 (Fig. 3). In the presence or absence of Ca2+, MG53 oligomers associated with wild-type C2A-GST, whereas MG53 monomers did not associate with wild-type C2A-GST. In the absence of DTT or NEM, MG53 existed as oligomers including dimers, which associated with WT C2A-GST only in 10 mM free Ca2+ (Fig. 3, top).
Next, we generated two mutant versions of C2A-GST (W52R or V67D) to further characterize the association between MG53 and the C2A domain. A V67D missense mutation in the human dysferlin gene has been found in patients with MM and patients with LGMD2B ; similarly, the W52R dysferlin missense mutation has been found in patients with LGMD2B . Each mutant C2A-GST, like the wild-type C2A, associated with MG53 oligomers when conditions included NEM in the presence or absence of Ca2+ (Fig. 3). However, the V67D mutation altered the calcium sensitivity of the association between C2A-GST and MG53 dimers; specifically, V67D-C2A-GST could associate with MG53 when conditions did not include NEM in the absence of Ca2+. In contrast, W52R-C2A-GST did not associate with MG53 when conditions did not include NEM in the presence or absence of Ca2+. These results revealed that the V67D mutation in the dysferlin C2A domain altered the Ca2+-dependence of the association between dysferlin and MG53 dimers.
MG53 with a C242A missense mutation shows impaired accumulation at wound sites and attenuates the formation of dysferlin patches
To examine the biological role of the association between dysferlin and MG53 in sarcolemmal repair, we used mouse skeletal muscle co-transfected with dysferlin-EGFP and RFP-tagged wild-type MG53 or RFP-tagged mutant MG53 to perform a membrane repair assay. The mutant MG53 carried a C242A missense mutation and is designated RFP-C242A-MG53 here. MG53 with a C242A missense mutation reportedly exists as a monomer or dimer when expressed in mammalian cells, but does not form oligomers via disulfide bonding [4,6]. RFP-C242A-MG53 did not accumulate at wound sites as reported previously, and it was associated with defective sarcolemmal repair . Co-expression of RFP-C242A-MG53 did not affect the subcellular localization of dysferlin in myofibers, and dysferlin was localized in a striated pattern (Fig. 4A). However, RFP-C242A-MG53 compromised the accumulation of dysferlin at injury sites (Fig. 4A, B). When the movement of dysferlin and wild-type MG53 were observed simultaneously in mouse skeletal muscle, RFP-wild-type MG53 accumulated more slowly at injury sites than dysferlin-EGFP (Fig. 4A). Accumulation of dysferlin-EGFP at wound sites stops within 5 seconds of injury and disperses gradually, while wild-type MG53 continues to accumulate for 200 seconds after injury (Fig. 4A and 4B).
MG53 accumulates normally at injury site of sarcolemma in dysferlin-deficient mice.
A previous study revealed that exogenous expression of MG53 in undifferentiated C2C12 cells was necessary for recruitment of GFP-dysferlin to sites of injury . Conversely, to examine whether the recruitment of MG53 requires dysferlin, and to elucidate the molecular pathology of dysferlinopathy, we used skeletal muscle from dysferlin-deficient A/J mice transfected with EGFP-MG53 to perform a membrane repair assay. We confirmed that EGFP-MG53 accumulated at sites of injury (Fig. 5). Sarcolemmal repair was observed and confirmed by FM4-46-loading in A/J mice (data not shown). The accumulation of MG53 at the sarcolemmal wound was observed in A/L mice, similar to wild-type mice. Similar results were obtained from the membrane repair assay using dysferlin-deficient SJL mice.
Both dysferlin and MG53 are involved in membrane repair after injury in skeletal muscle. Dysferlin accumulates at wounded sarcolemmal sites, and this accumulation requires the influx of Ca2+ into the myofiber . MG53 forms oligomers at the sarcolemmal injury site in an oxidation-dependent manner [4,6]. MG53 associates with dysferlin and facilitates vesicle trafficking to the site of membrane injury, and a recent finding suggests that MG53 and dysferlin may form a complex that participates in membrane repair in striated muscle . To characterize the association between dysferlin and MG53, we used an IP assay and mouse muscle extract with or without exogenously added EGTA or CaCl2 to examine the Ca2+ dependency of this association. Using lysis buffer that lacked EGTA and CaCl2, we observed the association of dysferlin with MG53 in mouse skeletal muscle. Lysates lacking exogenously added EGTA and CaCl2 contain physiological concentrations of free calcium. Hence, low concentrations of calcium are likely to be necessary for the interaction between MG53 and dysferlin.
Our results indicated that MG53 oligomers associated with the dysferlin C2A domain in the presence or absence of Ca2+, whereas MG53 dimers associated with the dysferlin C2A domain in a Ca2+-dependent manner. We also revealed that pathogenic mutations in the dysferlin C2A domain (W52R and V67D) alter the association between this domain and MG53 dimers in a pull-down assay. In the absence of EGTA or Ca2+, dysferlin with a C2A missense mutation (W52R or V67D) did not associate with MG53 in an IP assay that used extracts from co-transfected COS-7 cells; however, full-length dysferlin with the most common pathogenic mutation found in Japan, a W999C missense mutation in the dysferlin domain, did associate with MG53 in these IP assays (data not shown). These results indicate that the dysferlin C2A domain is important for the association between dysferlin and MG53. Amino acid W52 in human dysferlin is located between the b5-sheet and the b6-sheet, and V67 is located in the b6-sheet . Both residues are reportedly important for the C2 structure, particularly those of the b-sheet, and are predicted to coordinate calcium .
Recently, MG53 was reported to form homodimers, which are essential for MG53-mediated sarcolemmal repair . We used pull-down assays to investigate associations between MG53 monomers or MG53 dimers and the dysferlin C2A domain, and we found that MG53 dimers associated with dysferlin in a Ca2+-dependent manner. An increase in the cytoplasmic Ca2+ level is necessary for dysferlin accumulation at wounded sarcolemmal sites . The intracellular Ca2+ level is maintained at 50-100 nM in resting mammalian cells, but this increases to 6 μM after membrane puncture in Swiss-3T3 cells . The influx of extracellular Ca2+ through the wound site is required for vesicle fusion with the plasma membrane and formation of a repair patch in skeletal muscle, but MG53 trafficking to the wound site does not require Ca2+ . In pull-down assays in the present study, we demonstrated a selective association between the wild-type dysferlin C2A domain and MG53 dimers at a free Ca2+ concentration of 10 μM, but not at lower or higher free Ca2+ concentrations. These findings indicated that the concentration of free Ca2+ is important for association of dysferlin with MG53 dimers, and suggest that MG53 dimers not only form oligomers, but also associate with dysferlin in response to sarcolemmal injury. The altered Ca2+ sensitivity of the association between dysferlin with a mutation in the C2A domain and MG53 dimers in the pull-down assay also suggested that the C2A domain was important in the Ca2+-dependent association between dysferlin and MG53 dimers.
We were able to analyze the movement of dysferlin and MG53 in real time during sarcolemmal repair in a membrane repair assay that employs mouse myofibers that express dysferlin-EGFP and RFP-MG53. This is the first report to demonstrate that dysferlin and MG53 have different accumulation patterns at wound sites, and this result indicated that dysferlin and MG53 have different functions in sarcolemmal repair. Our studies also revealed that MG53 carrying a C242A missense mutation can suppress the accumulation of dysferlin at the wound site; this finding, together with results from pull-down assays, suggests that MG53 dimers play an important role in sarcolemmal repair.
Our studies also revealed that MG53 accumulated at injury sites in the sarcolemma in dysferlin-deficient mice, similar to wild-type mice. However, dysferlin-deficient SJL and A/J mice have a progressive muscular dystrophy phenotype, suggesting that MG53 is necessary but not sufficient for efficient sarcolemmal repair.
The authors have declared that no competing interests exist.
Address for correspondence : firstname.lastname@example.org (C. Matsuda)
- Liu J, Aoki M, Illa I, Wu C, Fardeau M, et al. (1998) Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet 20: 31-36.
- Bashir R, Britton S, Strachan T, Keers S, Vafiadaki E, et al. (1998) A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet 20: 37-42.
- Bansal D, Miyake K, Vogel SS, Groh S, Chen CC, et al. (2003) Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature 423: 168-172.
- Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, et al. (2009) MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol 11: 56-64.
- Cai C, Weisleder N, Ko JK, Komazaki S, Sunada Y, et al. (2009) Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3 and dysferlin. J Biol Chem.
- Hwang M, Ko JK, Weisleder N, Takeshima H, Ma J (2011) Redox-dependent oligomerization through a leucine zipper motif is essential for MG53-mediated cell membrane repair. Am J Physiol Cell Physiol 301: C106-114.
- Tagawa K, Ogawa M, Kawabe K, Yamanaka G, Matsumura T, et al. (2003) Protein and gene analyses of dysferlinopathy in a large group of Japanese muscular dystrophy patients. J Neurol Sci 211: 23-28.
- Ho M, Post CM, Donahue LR, Lidov HG, Bronson RT, et al. (2004) Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet 13: 1999-2010.
- Cai C, Masumiya H, Weisleder N, Pan Z, Nishi M, et al. (2009) MG53 regulates membrane budding and exocytosis in muscle cells. J Biol Chem 284: 3314-3322.
- Matsuda C, Kameyama K, Tagawa K, Ogawa M, Suzuki A, et al. (2005) Dysferlin interacts with affixin (beta-parvin) at the sarcolemma. J Neuropathol Exp Neurol 64: 334-340.
- Frangioni JV, Neel BG (1993) Solubilization and purification of enzymatically active glutathione S-transferase (pGEX) fusion proteins. Anal Biochem 210: 179-187.
- Aihara H, Miyazaki J (1998) Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16: 867-870.
- Cho W, Stahelin RV (2006) Membrane binding and subcellular targeting of C2 domains. Biochim Biophys Acta 1761: 838-849.
- Davis DB, Doherty KR, Delmonte AJ, McNally EM (2002) Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains. J Biol Chem 277: 22883-22888.
- Illarioshkin SN, Ivanova-Smolenskaya IA, Greenberg CR, Nylen E, Sukhorukov VS, et al. (2000) Identical dysferlin mutation in limb-girdle muscular dystrophy type 2B and distal myopathy. Neurology 55: 1931-1933.
- De Luna N, Freixas A, Gallano P, Caselles L, Rojas-Garcia R, et al. (2007) Dysferlin expression in monocytes: a source of mRNA for mutation analysis. Neuromuscular disorders : NMD 17: 69-76.
- Therrien C, Di Fulvio S, Pickles S, Sinnreich M (2009) Characterization of lipid binding specificities of dysferlin C2 domains reveals novel interactions with phosphoinositides. Biochemistry 48: 2377-2384.
- Steinhardt RA, Bi G, Alderton JM (1994) Cell membrane resealing by a vesicular mechanism similar to neurotransmitter release. Science 263: 390-393.